Comparison of different combination therapies for children with HBeAg positive chronic hepatitis B.
- Author:
Xun-hua ZHONG
1
;
Xin DENG
;
Xin-chun CHEN
;
Bo-ping ZHOU
Author Information
- Publication Type:Journal Article
- MeSH: Anti-HIV Agents; therapeutic use; Child; Child, Preschool; DNA, Viral; blood; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B Vaccines; therapeutic use; Hepatitis B e Antigens; blood; genetics; immunology; Hepatitis B virus; drug effects; genetics; immunology; Hepatitis B, Chronic; blood; drug therapy; Humans; Interferon-alpha; therapeutic use; Lamivudine; therapeutic use; Male; Treatment Outcome
- From: Chinese Journal of Experimental and Clinical Virology 2007;21(1):62-63
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the advantages of combination therapy with interferon-alpha plus nucleoside analogue-lamivudine or HBV vaccine in children with HBeAg positive chronic hepatitis B.
METHODSA total of 120 patients with HBeAg positive chronic hepatitis B were divided into three groups, 40 patients per group. Each group was treated with one of the following therapies respectively: Group A IFN-alpha 1b 10 MU/m2 three times per week (Tiw); Group B IFN-alpha 1b 10MU/m2 three times per week (Tiw) plus lamivudine 3 mg/kg for 6 months. Group C IFN-alpha 1b 10 MU/m2 three times per week (Tiw) plus HBV vaccine 30 microg one a month.
RESULTSThere was no significant difference in normalizing rate of ALT among the three groups at end of treatment. There was more significant difference in negative rate (seroconversion) of serum HBV DNA and HBeAg in group B than group A and group C (P less than 0.05).
CONCLUSIONThe combination therapy of IFN-alpha 1b plus lamivudine seemed to be more effective than the therapy with IFN-alpha alone and the combination of IFN-alpha and HBV vaccine.
